For research use only
| Cat No. | ABC-X0212C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The BCR-ABL (F317V) BAF3 Cell Line is designed for modeling ABL kinase inhibitor resistance and screening next-generation anti-leukemia agents.
The Human BCR_ABL (F317V) BAF3 Cell Line expresses the human BCR_ABL oncogene with a F317V substitution, introduced via lentiviral transduction into BAF3 cells. The resulting cell line proliferates independently of IL-3, providing a quantitative model for kinase inhibitor response assays.
Target
The F317V mutation in the BCR_ABL gene results in altered binding affinity for ABL kinase inhibitors, contributing to therapeutic resistance. This model replicates the drug resistance phenotype observed in patients with CML undergoing TKI treatment. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0212C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Ideal for high-throughput screening of TKI compounds, resistance mutation characterization, and optimization of novel targeted therapies.